Morphic Therapeutic (NASDAQ: MORF) announced participation in the Jefferies Next Generation IBD Therapeutics Virtual Summit on September 23, 2020. The management team will engage in a panel discussion at 8:45 a.m. ET and present a company overview at 1:00 p.m. ET. A live webcast will be accessible via the Investor section of Morphic's website, with an archived replay available post-conference. Morphic specializes in developing oral therapies targeting integrins to treat serious chronic diseases, using its proprietary MInT technology platform in collaborations with major pharmaceutical firms.
Morphic Therapeutic, a biopharmaceutical company focused on oral integrin therapies for chronic diseases, will participate in several investor conferences. CEO Praveen Tipirneni will join a fireside chat at the Wells Fargo Virtual Healthcare Conference on September 10 at 8:40 am ET. Additionally, the management team will hold virtual meetings during the Citi 15th Annual BioPharma Virtual Conference from September 8 to 11. A live webcast of the Wells Fargo session will be available on Morphic's website, along with an archived replay post-conference.
Morphic Therapeutic (NASDAQ: MORF) has announced that AbbVie (NYSE: ABBV) will pay a $20 million license fee following their collaboration on αvβ6 integrin inhibitors for fibrotic diseases. AbbVie will take over further development and commercialization efforts for these inhibitors, including MORF-720 and MORF-627. This collaboration highlights the potential of Morphic's MInT platform and its preclinical data supporting these treatments for conditions like idiopathic pulmonary fibrosis. Morphic is also eligible for future milestone payments and tiered royalties from sales.
Morphic Therapeutic (NASDAQ: MORF) has presented new data on its oral small molecule candidate, MORF-057, at the 2020 Digestive Disease Week (DDW). The data confirm MORF-057's ability to selectively target the integrin α4β7, which is significant for treating inflammatory bowel disease (IBD). Key findings include >90% receptor occupancy in non-human primates and comparable potency to existing therapies. An Investigational New Drug Application is on track for mid-2020, with a Phase 1 trial anticipated in Q3 2020. The results bolster MORF-057's profile as a promising treatment for IBD.
Summary not available.